Abstract
Aims
Objective of this study was to compare the assay characteristics of a new fecal calprotectin rapid test with an enzyme-linked immunosorbent assay (ELISA). The second aim was to assess the potential of measuring fecal calprotectin as screening method for intestinal inflammation and colorectal malignancies.
Patients and methods
One hundred forty patients with lower gastrointestinal symptoms referred to colonoscopy provided fecal samples (56, control group; 18, diverticulosis; 29, colorectal adenoma; 8, colorectal carcinoma (CRC); 18, active inflammatory bowel disease (IBD); 11, intestinal infections). Feces were analyzed by two assay methods.
Results
Compared to the control group (median 25.8 µg/g), calprotectin levels were significantly increased in adenoma (66.3 µg/g), CRC (164 µg/g), intestinal infections (306 µg/g), and active IBD (797 µg/g). An adequate diagnostic accuracy could be found for active IBD with a sensitivity, specificity, and an area under the curve (AUC) of 100%, 79%, and 0.955 (ELISA) vs. 89%, 80%, and 0.896 (rapid test). Similar results were obtained for CRC (100%, 79%, 0.922 vs. 100%, 80%, 0.948) whereas in adenomas a low sensitivity, specificity, and AUC of 55%, 79%, and 0.686 vs. 52%, 80%, and 0.666 were found for fecal calprotectin.
Conclusions
Both fecal calprotectin assays are effective in identifying active IBD and CRC but lack analytical sensitivity in separating CRC from adenoma as well as adenoma from the control group. The new calprotectin rapid test is a convenient method for assessing the calprotectin level in an outpatient setting. Henceforth, it provides a precondition for the fecal calprotectin method to challenge fecal occult blood testing in further evaluations.
Similar content being viewed by others
References
Gearry R, Barclay M, Florkowski C, George P, Walmsley T (2005) Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation. NZMJ 118:1444–1451
Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F et al (2003) Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49:861–867
Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C et al (2005) Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 54:364–368
Gaya D, Mackenzie JFR (2002) Faecal calprotectin: a bright future for assessing disease activity in Crohn’s disease. Q J Med 95:557–558
Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ et al (2000) Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 95:2831–2837
Poullis A, Foster R, Northfield TC, Mendall MA (2002) Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 16:675–681
Røseth AG, Schmidt PN, Fagherol MK (1999) Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with Inflammatory bowel disease. Scand J Gastroenterol 34:50–54
Røseth AG, Aadland E, Grzyb K (2004) Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 39:1017–1020
Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S et al (2000) A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 47:506–513
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I (2000) Surrogate markers of intestinal inflammation are predictive in relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22
Tibble JA, Bjarnason I (2001) Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 7:460–465
Vermeire S, Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic or unnecessary toys? Gut 55:426–431
Johne B, Kronborg O, Tøn H, Kristinsson J, Fuglerud P (2001) A new faecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous methods. Scand J Gastroenterol 36:291–296
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I (1998) Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 41:316–321
Kristinsson J, Armbruster CHR, Ugstad M, Kriwanek S, Nygaard K, Ton H et al (2001) Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol 36:202–207
Limburg PJ, Devens ME, Harrington JJ, Diehl NN, Mahoney DW, Ahlquist DA (2003) Prospective evaluation of fecal calprotectin as screening biomarker for colorectal neoplasia. Am J Gastroenterol 98:2299–2305
Poullis A, Foster R, Shetty A, Fagherol MK, Mendall MA (2004) Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomark Prev 13:279–284
Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K et al (1993) Fecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 28:1073–1076
Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagherol M, Bjarnason I (2001) Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49:402–408
Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH et al (2000) Faecal calprotectin levels in a high risk population of colorectal neoplasia. Gut 46:795–800
Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK (1990) Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336:763–765
Yui S, Mikami M, Tsurumaki K, Yamazaki M (1997) Growth inhibitory and apoptosis inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions. J Leukoc Biol 61:50–57
Fagherol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I (1990) Calprotectin (the L1 leucocyte protein). In: Smith VL, Dedman JR (eds) Stimulus response coupling: the role of intracellular calcium-binding proteins. CRC, Boca Raton, pp 187–210
Brun JG, Ulvestad E, Fagherol MK, Jonsson R (1994) Effects of human calprotectin (L1) on in vitro immunoglobulin syntheses. Scand J Immunol 40:675–680
Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF et al (1997) Functional and clinical aspects of the myelomonocyte protein calprotectin. J Clin Pathol 50:113–123
Summerton CB, Longlands MG, Wiener K, Shreeve DR (2002) Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14:841–845
Røseth AG, Fagherol MK, Aadland E, Schjonsby H (1992) Assessment of the neutrophil dominating protein calprotectin in feces. Scand J Gastroenterol 27:793–798
Tibble JA, Sigthorsson G, Foster R, Fagherol MK, Røseth A, Bjarnasson I (1999) High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 45:362–366
Tibble JA, Sigthorsson G, Foster R et al (1998) NSAID enteropathy: a new simple diagnostic test. Gut 42:142
Fagherol MK (2000) Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 356:1783–1784
Husebye E, Tøn H, Johne B (2001) Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 96(9):2683–2687
von Roon CA, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP et al (2007) Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 102:1–11
Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I (2002) Use of surrogate markers of inflammation and Rome criteria to distinguish organic from non-organic intestinal disease. Gastroenterology 123:450–460
D’Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG et al (2007) Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 22:429–437
Kristinsson J, Nygaard K, Aadland E, Barstad S, Sauar J, Hofstad B et al (2001) Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II. Digestion 64:104–110
Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH (2004) Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 53:1329–1333
Fagerberg UL, Lööf L, Myrdal U, Hansson L-O, Finkel Y (2005) Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. JPGN 40:450–455
Acknowledgements
The authors gratefully acknowledge the excellent assistance of Prof. W. Zoller, MD, A. Schreiber, MD, (Katharinenhospital), E. Fröhlich, MD, M. Schmidt, MD, (Karl-Olga-Hospital), Prof. E. Stange, MD, (Robert-Bosch-Hospital), H. Gölkel, MD, Th. Bühler MD, Prof. B. Klump, MD, K. Teubner, MD, D. Vogler, MD, A. Maier, MD, and A. Mühlhöfer, MD, in recruiting patients and kindly providing samples.
Author information
Authors and Affiliations
Corresponding author
Additional information
Support for analytical kits: Prevista GmbH & Co. KG, Munich, Germany.
Rights and permissions
About this article
Cite this article
Damms, A., Bischoff, S.C. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 23, 985–992 (2008). https://doi.org/10.1007/s00384-008-0506-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-008-0506-0